Phibro Animal Health Corporation (NASDAQ: PAHC) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
Phibro Animal Health Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $34.92, Phibro Animal Health Corporation trades at 13.7x trailing earnings, 0.9x sales and 3.4x book value, with an EV/EBITDA of 9.0. Over the last twelve months it generated about $1.5B of revenue and $104M of net income. It runs a gross margin of 33.8%, an operating margin of 13.0% and a net margin of 6.7%. It shows return on equity of 27.4%, return on invested capital of 11.7% and a free cash flow yield of 1.5%. On the balance sheet: a debt-to-equity ratio of 1.89 and a current ratio of 3.20. Over the past 52 weeks the share price ranged from $28.25 to $60.08, with a beta of 0.42.
Phibro Animal Health Corporation pays a dividend yielding 1.38%, with 19% of earnings paid out. Its Maz Dividend Score is 1.57 out of 5, ranked against the other dividend payers in its sector (Safety 2.37, Growth 1.43, Yield 3.70, Consistency 2.12).
14 Wall Street analyst ratings cover the stock: 6 Buy, 4 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Phibro Animal Health Corporation (PAHC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 49.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.47% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 49.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.59% / 33% · Receivables / Mkt Cap (36m) 14.9% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 49.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.59% / 33.33% · Receivables / Mkt Cap (24m) 14.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 50.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 5.40% / 33.33% · Receivables / Avg Assets (4Q) 15.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 48.5% / 33.33% · (Cash+ST Inv) / Total Assets 5.49% / 33.33% · (Cash+Recv) / Total Assets 20.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Phibro Animal Health Corporation (PAHC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Phibro Animal Health Corporation is over the AAOIFI limit on Debt / Mkt Cap (36m).
Phibro Animal Health Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.